Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT07226466

Conditions

Brain Tumor Adult

Brain Metastases From Solid Tumors

Brain Tumor, Primary

Brain Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Blood sample

Brain magnetic resonance imaging (MRI)

Brain Health Assessment

Quality of Life (QoL) Questionnaire

Study Details

Brief summary:

This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.

Conditions

Brain Tumor Adult

Brain Metastases From Solid Tumors

Brain Tumor, Primary

Brain Tumor

Study ID

NCT07226466

Start date

Nov 2, 2026

Status verified date

Nov, 2026

Completion date

Aug 31, 2029

Anticipated

Primary completion date

Feb 28, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. >= 18 years old
2. Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.
3. Diagnosis of primary solid tumor and secondary involvement of the brain
4. If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none > 1 cm in max diameter.
5. Candidate for standard of care / usual care (SOC) focused brain radiotherapy.
6. No prior brain radiotherapy, including whole brain radiotherapy.
7. Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.
8. Estimated life expectancy post-treatment of > 2 years.

Exclusion Criteria:

1. Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).
2. Diagnosis of memory disorder pre-treatment.
3. Leptomeningeal disease or disease involving either hippocampus.

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Arms

Adults with Brain Tumor Receiving Radiotherapy

The study entails longitudinal assessment of plasma biomarkers (Aβ, GFAP, phospho Tau, NfL), determination of APOE genotype, neuropsychiatric testing Brain Health Assessment test (BHA), a clinically validated neurocognitive battery compiling metrics on memory and language), and brain morphometric measurements synchronized with standard of care brain MRIs.

Interventions

Blood sample

Blood sample will be collected

Brain magnetic resonance imaging (MRI)

Brain MRI will be performed during the course of data collection

Brain Health Assessment

Brain Health Assessment will be performed during the course of data collection

Quality of Life (QoL) Questionnaire

QoL questionnaire will be given to participants during the course of data collection

Primary outcome measure

  • Mean change in serum Amyloid-beta peptide (Aβ) [ Time Frame: Up to 6 months ]
  • Mean change in serum Amyloid-beta peptide (Aβ) by APOE genotype [ Time Frame: Up to 6 months ]
  • Mean change of score on the European Organization for Research and Treatment of Cancer quality of life questionnaire - Brain Module (EORTC-QLQ-BN20) [ Time Frame: Up to 18 months from date of first radiation dose ]
  • Mean change in serum Glial Fibrillary Acidic Protein (GFAP) [ Time Frame: Up to 6 months ]
  • Mean change in serum Glial Fibrillary Acidic Protein (GFAP) by APOE genotype [ Time Frame: Up to 6 months ]
  • Mean change in serum Phosphorylated TAU (p-TAU) [ Time Frame: Up to 6 months ]
  • Mean change in serum Phosphorylated TAU (p-TAU) by APOE genotype [ Time Frame: Up to 6 months ]
  • Mean change in serum Neurofilament Light Chain (NfL) [ Time Frame: Up to 6 months ]
  • Mean change in serum Neurofilament Light Chain (NfL) by APOE genotype [ Time Frame: Up to 6 months ]
  • Mean change in Brain Health Assessment by APOE genotype [ Time Frame: Up to 6 months ]
  • Mean change in Hippocampal Volume [ Time Frame: Up to 6 months ]
  • Mean change in Hippocampal Volume by APOE genotype [ Time Frame: Up to 6 months ]

Central Contacts and Locations

Central contacts

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

More Information

Sponsor

University of California, San Francisco

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.